Clinical Trial

A Phase 1 Study of BHV-1530 in Advanced Solid Tumors

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This is a Phase 1, first in human (FIH), Open-Label, Dose Escalation, Dose Expansion and Dose Optimization Study of BHV-1530 as Monotherapy and in Combination with Other Anti-Cancer Agents in Adult Participants with Advanced or Metastatic Solid Tumors
Protocol Amendment History 4 changes
critical Primary endpoint(s) modified 2026-07-10
notable Enrollment increased: 95 -> 140 participants 2026-07-10
minor Trial arms changed: 1 -> 2 2026-07-10
notable Trial sites expanded: 13 -> 17 locations 2026-07-10
Trial Details
NCT Number NCT06874335
Lead Sponsor Biohaven Therapeutics Ltd.
Conditions Solid Tumor
Enrollment 140 participants
Start Date 2025-03-20
Primary Completion 2029-03 (estimated)
Study Completion 2029-03 (estimated)
Updated on ClinicalTrials.gov 2026-07-09